Industry Application
Pyrimidine intermediates (e.g. 4,5,6-trichloropyrimidine, 4-chloropyrrolo[2,3-d]pyrimidine, 6-amino-5-chloropyrimidine-4-carboxylic acid) are common heterocyclic cores in antitumor, antiviral and nervous-system drug molecules, enabling regioselective functionalization via nucleophilic substitution to build active scaffolds.
Chiral intermediates (e.g. L-Prolinamide) and fluoro-/sulfur-containing aromatic intermediates introduce chiral centers and specific pharmacophores, helping manufacturers precisely control stereochemistry and impurity profiles in asymmetric synthesis and SAR studies.
For batch consistency and impurity control in scale-up, we collaborate across specification communication, sample validation and stable delivery to safeguard intermediate quality across multi-step synthesis.
Pyrimidine API intermediate project
In pyrimidine-scaffold API intermediate synthesis, regioselectivity across multi-step nucleophilic substitution was hard to control with high by-product share and ±8% batch yield swings, hurting scale-up.
Adopted our high-purity 4,5,6-trichloropyrimidine as a key intermediate, with specification communication, batch-consistency support and stable supply.
Achieved highly regioselective functionalization; target-product yield rose from 70% to 92% with markedly reduced batch variance and stable scale-up.
Chiral intermediate synthesis project
Optical purity and batch consistency of chiral intermediates directly affect downstream drug quality; standard-grade impurity variation caused unstable ee values in asymmetric synthesis.
Offered specification communication and small-batch samples of L-Prolinamide and other chiral intermediates, with process validation and impurity-profile control.
Chiral purity stabilized above 92% with markedly higher first-pass yield; downstream API quality stayed stable and controllable.
Old process pain points on the left, our new solutions on the right — quantified efficiency, cost and quality gains.
Low regioselectivity, many by-products
- Multi-step substitution selectivity hard to control, high by-product share
- Intermediate batch variation caused unstable downstream yield
- Yield swings ±8% batch-to-batch, hurting scale-up
High regioselectivity, batch-stable
- High-purity pyrimidine intermediate, regioselectivity >95%
- Batch-consistency specification, stable impurity profile
- Downstream yield variance narrowed to ±2%
Adopting our high-purity 4,5,6-trichloropyrimidine with specification communication raised target-product yield from 70% to 92% with markedly reduced batch variance.
Low chiral purity, impurity swings
- Standard-grade impurity variation triggered side reactions
- Unstable chiral ee required repeated purification
- Downstream API quality was inconsistent batch-to-batch
Stable ee, batch-consistent
- Chiral-grade communication, controlled impurity profile
- ee stable above 92%, first-pass compliant
- Small-batch validation support, stable downstream quality
Using L-Prolinamide and other chiral intermediates with process validation stabilized ee above 92% and notably improved downstream API quality.
![4-Chloropyrrolo[2,3-d]pyrimidine](/uploads/hualun/Uploads/pro_p29.jpg)
Need further discussion?
Contact us for product data, application advice and supply support.